Skip to main content

NANOINGENIERIA APLICADA A SISTEMAS DE ADMINISTRACION EFICIENTE DE FARMACOS BASADOS EN LA DEFENSA DEL HUESPED POR VIA INTRANASAL

PID2019-107298RB-C22

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi|||0000-0001-5750-550X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez-Matínez, Merce
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Villaverde, Antonio|||0000-0002-2615-4521
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases.
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Design strategies for positively charged endolysins: Insights into Artilysin development

  • Carratalá, Jose Vicente
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Ferrer-Miralles, Neus
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature., The authors are indebted to Agencia Española de Investigación for the granted project (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EGF and AA and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NFM), to Marató de TV3 foundation (grant 201812-30-31-32-33) and to AGAUR for project 2021 SGR 01552. The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JVCT is supported with a Margarita Salas grant for the training of young doctoral graduates (722713)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi
  • Tarrés Freixas, Ferran
  • Favaro, Marianna T.P.
  • Lascorz, Jara
  • Marquez-Matínez, Merce
  • Mendoza, Rosa
  • Corchero, José Luís
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus
  • Vazquez, Esther
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Villaverde, Antonio
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases., The project was mainly funded by AGAUR (grant number 2020PANDE00003) and CIBER-Consorcio Centro de Investigación Biomédica en Red- (grant number CB06/01/0014), through the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, within the intramural project NANOSARS (to E.P.). We also gratefully acknowledge the support from AEI for the development of multimeric recombinant drugs (grant numbers PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22/AEI/10.13039/501100011033 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). Our team also received support from AGAUR for our activities in drug design (grant number 2021SGR00092 to A.V.). Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp). IRTA is supported by CERCA Programme/Generalitat de Catalunya. The authors also acknowledge the invaluable assistance of the animal caretakers at the BSL3 facility at IRTA., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, Jose Vicente
  • Ferrer‐Miralles, Neus
  • Garcia-Fruitos, Elena
  • Arís, Anna
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively., The authors are indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. The authors acknowledge financial support from the Agencia Española de Investigación for the granted projects (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EG-F and AA, and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NF-M) and to AGAUR for project 2021 SGR 01552. JVC is supported with a Margarita Salas grant for the training of young doctoral graduates (grant no. 722713)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi
  • Tarrés Freixas, Ferran
  • Favaro, Marianna T.P.
  • Lascorz, Jara
  • Marquez-Matínez, Merce
  • Mendoza, Rosa
  • Corchero, José Luís
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus
  • Vazquez, Esther
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Villaverde, Antonio
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases., The project was mainly funded by AGAUR (grant number 2020PANDE00003) and CIBER-Consorcio Centro de Investigación Biomédica en Red- (grant number CB06/01/0014), through the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, within the intramural project NANOSARS (to E.P.). We also gratefully acknowledge the support from AEI for the development of multimeric recombinant drugs (grant numbers PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22/AEI/10.13039/501100011033 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). Our team also received support from AGAUR for our activities in drug design (grant number 2021SGR00092 to A.V.). Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp). IRTA is supported by CERCA Programme/Generalitat de Catalunya. The authors also acknowledge the invaluable assistance of the animal caretakers at the BSL3 facility at IRTA., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Design strategies for positively charged endolysins: Insights into Artilysin development

  • Carratalá, Jose Vicente
  • Alomar, Oscar
  • Garcia-Fruitos, Elena
  • Ferrer-Miralles, Neus
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature., The authors are indebted to Agencia Española de Investigación for the granted project (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EGF and AA and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NFM), to Marató de TV3 foundation (grant 201812-30-31-32-33) and to AGAUR for project 2021 SGR 01552. The authors are also indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. JVCT is supported with a Margarita Salas grant for the training of young doctoral graduates (722713)., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, Jose Vicente
  • Ferrer‐Miralles, Neus
  • Garcia-Fruitos, Elena
  • Arís, Anna
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively., The authors are indebted to the CERCA Program (Generalitat de Catalunya) and European Social Fund for supporting our research. The authors acknowledge financial support from the Agencia Española de Investigación for the granted projects (PID2019-107298RB-C21/AEI/10.13039/501100011033 to EG-F and AA, and PID2019-107298RB-C22/AEI/10.13039/501100011033 to NF-M) and to AGAUR for project 2021 SGR 01552. JVC is supported with a Margarita Salas grant for the training of young doctoral graduates (grant no. 722713)., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

Raw data to support the manuscript with the following intended title, The poly-histidine tag H6 mediates structural and functional properties of disintegrating bacterial amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Serna, Naroa|||0000-0001-5682-8198
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Nolan, Verónica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Raw data of a set of experiments aimed to explore the involvement of His-tags in the formation of bacterial inclusion bodies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Biofabrication of functional protein nanoparticles through simple His-tag engineering

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Serna, Naroa|||0000-0001-5682-8198
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Flores, Sandra
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Nolan, Verónica
  • de Marco, Ario|||0000-0001-7729-819X
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
We have developed a simple, robust, and fully transversal approach for thea-la-cartefabrication of functional multimeric nanoparticles with potential biomedical applications, validated here by a set of diverse and unrelated polypeptides. The proposed concept is based on the controlled coordination between Znions and His residues in His-tagged proteins. This approach results in a spontaneous and reproducible protein assembly as nanoscale oligomers that keep the original functionalities of the protein building blocks. The assembly of these materials is not linked to particular polypeptide features, and it is based on an environmentally friendly and sustainable approach. The resulting nanoparticles, with dimensions ranging between 10 and 15 nm, are regular in size, are architecturally stable, are fully functional, and serve as intermediates in a more complex assembly process, resulting in the formation of microscale protein materials. Since most of the recombinant proteins produced by biochemical and biotechnological industries and intended for biomedical research are His-tagged, the green biofabrication procedure proposed here can be straightforwardly applied to a huge spectrum of protein species for their conversion into their respective nanostructured formats.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antibacterial activity of T22, a specific peptidic ligand of the tumoral marker CXCR4

  • Serna, Naroa|||0000-0001-5682-8198
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Serna, Naroa|||0000-0001-5682-8198
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Nolan, Verónica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The coordination between histidine-rich peptides and divalent cations supports the formation of nano- and micro-scale protein biomaterials, including toxic and non-toxic functional amyloids, which can be adapted as drug delivery systems. Among them, inclusion bodies (IBs) formed in recombinant bacteria have shown promise as protein depots for time-sustained protein release. We have demonstrated here that the hexahistidine (H6) tag, fused to recombinant proteins, impacts both on the formation of bacterial IBs and on the conformation of the IB-forming protein, which shows a higher content of cross-beta intermolecular interactions in H6-tagged versions. Additionally, the addition of EDTA during the spontaneous disintegration of isolated IBs largely affects the protein leakage rate, again protein release being stimulated in His-tagged materials. This event depends on the number of His residues but irrespective of the location of the tag in the protein, as it occurs in either C-tagged or N-tagged proteins. The architectonic role of H6 in the formation of bacterial IBs, probably through coordination with divalent cations, offers an easy approach to manipulate protein leakage and to tailor the applicability of this material as a secretory amyloidal depot in different biomedical interfaces. In addition, the findings also offer a model to finely investigate, in a simple set-up, the mechanics of protein release from functional secretory amyloids.
Dipòsit Digital de Documents de la UAB
Research data Set de datos (Dataset)

Raw research data supporting results shown in the manuscript "Toxicity profiling of bacterial inclusion bodies in human Caco-2 cells"

  • Barguilla, Irene|||0000-0003-1081-4457
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Hernández, Alba|||0000-0001-6938-1233
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Raw data collected directly from a primary source and has not been processed in any way to address the hypothesis of the potential tocicity of Inclusion bodies (IBs) obtained from different prokaryotic hosts.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Toxicity Profiling of Bacterial Inclusion Bodies in Human Caco-2 Cells

  • Barguilla, Irene|||0000-0003-1081-4457
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Hernández, Alba|||0000-0001-6938-1233
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Bacterial inclusion bodies (IBs) are discrete macromolecular complexes that appear in recombinant prokaryotic cells under stress conditions. These structures are often discarded for biotechnological uses given the difficulty recovering proteins of interest from them in a soluble form. However, recent approaches have revealed the potential of these protein clusters as biomaterials to promote cell growth and as protein depots for the release of recombinant proteins for biotechnological and biomedical applications. Although these kinds of natural supramolecular complexes have attracted great interest, no comprehensive study of their toxicity in cell cultures has been carried out. In this study, Caco-2 cells were exposed to natural IBs, soluble protein-only nanoparticles (NPs), and non-assembled versions of the same protein for comparative purposes. Cytotoxicity, oxidative stress and genotoxicity were analyzed for all these protein formats. Natural IBs and soluble protein formats demonstrated their safety in eukaryotic cells. No cytotoxicity, genotoxicity or oxidative stress was detected in Caco-2 cells exposed to the protein samples in any of the experimental conditions evaluated, which covered protein concentrations used in previous biological activity assays. These conditions evaluated the activity of protein samples obtained from three prokaryotic hosts (Escherichia coli and the endotoxin-free expression systems Lactococcus lactis and ClearColi® BL21 (DE3)). Our results demonstrate that natural IBs and soluble protein nanoparticles are non-toxic materials for eukaryotic cells, and that this may represent an interesting alternative to the classical unassembled format of recombinant proteins for certain applications in biotechnology and biomedicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant vaccines in 2022, a perspective from the cell factory

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80's, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery, A Host Comparative Overview

  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferreira, Luis|||0000-0002-4883-1693
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Parladé, Eloi|||0000-0001-5750-550X
By following simple protein engineering steps, recombinant proteins with promising applications in the field of drug delivery can be assembled in the form of functional materials of increasing complexity, either as nanoparticles or nanoparticle-leaking secretory microparticles. Among the suitable strategies for protein assembly, the use of histidine-rich tags in combination with coordinating divalent cations allows the construction of both categories of material out of pure polypeptide samples. Such molecular crosslinking results in chemically homogeneous protein particles with a defined composition, a fact that offers soft regulatory routes towards clinical applications for nanostructured protein-only drugs or for protein-based drug vehicles. Successes in the fabrication and final performance of these materials are expected, irrespective of the protein source. However, this fact has not yet been fully explored and confirmed. By taking the antigenic RBD domain of the SARS-CoV-2 spike glycoprotein as a model building block, we investigated the production of nanoparticles and secretory microparticles out of the versions of recombinant RBD produced by bacteria (Escherichia coli), insect cells (Sf9), and two different mammalian cell lines (namely HEK 293F and Expi293F). Although both functional nanoparticles and secretory microparticles were effectively generated in all cases, the technological and biological idiosyncrasy of each type of cell factory impacted the biophysical properties of the products. Therefore, the selection of a protein biofabrication platform is not irrelevant but instead is a significant factor in the upstream pipeline of protein assembly into supramolecular, complex, and functional materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Design strategies for positively charged endolysins, Insights into Artilysin development

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Arís i Giralt, Anna|||0000-0001-7830-888X
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Endolysins are bacteriophage-encoded enzymes that can specifically degrade the peptidoglycan layer of bacterial cell wall, making them an attractive tool for the development of novel antibacterial agents. The use of genetic engineering techniques for the production and modification of endolysins offers the opportunity to customize their properties and activity against specific bacterial targets, paving the way for the development of personalized therapies for bacterial infections. Gram-negative bacteria possess an outer membrane that can hinder the action of recombinantly produced endolysins. However, certain endolysins are capable of crossing the outer membrane by virtue of segments that share properties resembling those of cationic peptides. These regions increase the affinity of the endolysin towards the bacterial surface and assist in the permeabilization of the membrane. In order to improve the bactericidal effectiveness of endolysins, approaches have been implemented to increase their net charge, including the development of Artilysins containing positively charged amino acids at one end. At present, there are no specific guidelines outlining the steps for implementing these modifications. There is an ongoing debate surrounding the optimal location of positive charge, the need for a linker region, and the specific amino acid composition of peptides for modifying endolysins. The aim of this study is to provide clarity on these topics by analyzing and comparing the most effective modifications found in previous literature.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced recombinant protein capture, purity and yield from crude bacterial cell extracts by N-Lauroylsarcosine-assisted affinity chromatography

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Background: Recombinant proteins cover a wide range of biomedical, biotechnological, and industrial needs. Although there are diverse available protocols for their purification from cell extracts or from culture media, many proteins of interest such as those containing cationic domains are difficult to purify, a fact that results in low yields of the final functional product. Unfortunately, this issue prevents the further development and industrial or clinical application of these otherwise interesting products. Results: Aiming at improving the purification of such difficult proteins, a novel procedure has been developed based on supplementing crude cell extracts with non-denaturing concentrations of the anionic detergent N-Lauroylsarcosine. The incorporation of this simple step in the downstream pipeline results in a substantial improvement of the protein capture by affinity chromatography, an increase of protein purity and an enhancement of the overall process yield, being the detergent not detectable in the final product. Conclusion: By taking this approach, which represents a smart repurposing of N-Lauroylsarcosine applied to protein downstream, the biological activity of the protein is not affected. Being technologically simple, the N-Lauroylsarcosine-assisted protein purification might represent a critical improvement in recombinant protein production with wide applicability, thus smothering the incorporation of promising proteins into the protein market.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Rueda, Ariana|||0000-0001-7588-9279
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez-Alba, Lucía|||0000-0001-7353-1097
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Nanoscale protein materials show increasing applications in biotechnology and biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein oligomerization is reachable through several engineering approaches, including the use of divalent cations for histidine-rich stretches, the effectiveness of cation-His binding is influenced by protein conformation, media composition, and chelating agents. Thus, looking for powerful, green, cross-linker-free, and transversal oligomerization platforms, we have built a histidine-templated cysteine-coupling concept. On this basis, we have engineered a Cys-containing, H6-derived His-Cys hybrid tag that enables the spontaneous and efficient self-assembling of tagged proteins into monodisperse nanoparticles through a highly ordered covalent binding process. Although the generated nanostructures are supported by disulfide bridge formation and exclusively reversed by reducing agents but not by chelating agents, the presence of cysteine residues does not disrupt the metal-binding abilities of histidine residues within the tag. This fact allows one to combine the one-step IMAC-based protein purification and, also, the Zn2+-induced formation of higher-order microparticulate materials as nanoparticle-releasing protein-only depots. The dual mode of cross-molecular interactivity shown by the hybrid tag and the structural robustness and stability of the resulting nanoparticles offer wide applicability of the green biofabrication concept proposed here for the further development of clinically usable protein materials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez, Merce
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Ferreira, Luis|||0000-0002-4883-1693
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Parladé, Eloi|||0000-0001-5750-550X
  • Villaverde, Antonio|||0000-0002-2615-4521
The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

LysJEP8, A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Garcia-Fruitos, Elena|||0000-0001-7498-4864
  • Arís i Giralt, Anna|||0000-0001-7830-888X
Antimicrobial resistance (AMR) is an escalating global health crisis, driven by the overuse and misuse of antibiotics. Multidrug-resistant Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, are particularly concerning due to their high morbidity and mortality rates. In this context, endolysins, derived from bacteriophages, offer a promising alternative to traditional antibiotics. This study introduces LysJEP8, a novel endolysin derived from Escherichia phage JEP8, which exhibits remarkable antimicrobial activity against key Gram-negative members of the ESKAPE group. Comparative assessments highlight LysJEP8's superior performance in reducing bacterial survival rates compared to previously described endolysins, with the most significant impact observed against P. aeruginosa, and notable effects on A. baumannii and K. pneumoniae. The study found that LysJEP8, as predicted by in silico analysis, worked best at lower pH values but lost its effectiveness at salt concentrations close to physiological levels. Importantly, LysJEP8 exhibited remarkable efficacy in the disruption of P. aeruginosa biofilms. This research underscores the potential of LysJEP8 as a valuable candidate for the development of innovative antibacterial agents, particularly against Gram-negative pathogens, and highlights opportunities for further engineering and optimization to address AMR effectively.